Diagnostic significance of S100A2 and S100A6 levels in sera of patients with non-small cell lung cancer

Tumor Biology

Volumn 37, Issue 2, 2016, Pages 2299-2304

  Wang, Ting ^a,b   Liang, Yiqian ^a   Thakur, Asmitananda ^a,c,d   Zhang, Shuo ^a   Yang, Tian ^a   Chen, Tianjun ^a   Gao, Lei ^a   Chen, Mingwei ^a   Ren, Hui ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b XI AN NO 4 HOSPITAL   (China)

^c Life Guard Hospital   (Nepal)

^d SR Laboratory and Diagnostic Center   (Nepal)

Author keywords

Biomarkers; Calcium binding protein; Non small cell lung cancer; S100A2; S100A6

Indexed keywords

CALCIUM BINDING PROTEIN; CALCYCLIN; PROTEIN S100A2; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; CHEMOTACTIC FACTOR; PROTEIN S 100; S100A2 PROTEIN, HUMAN; S100A6 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL LUNG CARCINOMA; AGED; AREA UNDER THE CURVE; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS;

ADULT; AGED; AREA UNDER CURVE; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; CHEMOTACTIC FACTORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ROC CURVE; S100 PROTEINS; SENSITIVITY AND SPECIFICITY;

EID: 84941359635     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-4057-z     Document Type: Article

References (31)

1. Yu H, Han Z, Wang Y, Xin H. The clonal evolution and therapeutic approaches of lung cancer. Cell Biochem Biophys. 2014;70:63–71.
2. Travis WD. Classification of lung cancer. Semin Roentgenol. 2011;46:178–86.
3. Travis WD, Rekhtman N. Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing. Semin Respir Crit Care Med. 2011;32:22–31.
4. Nicholson AG, Gonzalez D, Shah P, Pynegar MJ, Deshmukh M, Rice A, et al. Refining the diagnosis and egfr status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, ttf-1, cytokeratin 5/6, and p63, and egfr mutation analysis. J Thorac Oncol. 2010;5:436–41.
5. Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol. 2013;31:992–1001.
6. Claiborne PM, Fowler CS, Vaporciyan AA. Follow-up of patients with resected thoracic malignancies. Thorac Surg Clin. 2012;22:123–31.
7. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8–29.
8. Li X, Lu J, Ren H, Chen T, Gao L, Di L, et al. Combining multiple serum biomarkers in tumor diagnosis: a clinical assessment. Mol Clin Oncol. 2013;1:153–60.
9. Smith RA, Cokkinides V, Brooks D, Saslow D, Shah M, Brawley OW. Cancer screening in the United States, 2011: a review of current american cancer society guidelines and issues in cancer screening. CA cancer J Clin. 2011;61:8–30.
10. Chen HY, Xu CS, Jin QE, Liu ZH. S100 protein family in human cancer. Am J Cancer Res. 2014;4:89–115.
11. Stradal TB, Troxler H, Heizmann CW, Gimona M. Mapping the zinc ligands of s100a2 by site-directed mutagenesis. J Biol Chem. 2000;275:13219–27.
12. Nacken W, Roth J, Sorg C, Kerkhoff C. S100a9/s100a8: Myeloid representatives of the s100 protein family as prominent players in innate immunity. Microsc Res Tech. 2003;60:569–80.
13. Donato R. Intracellular and extracellular roles of s100 proteins. Microsc Res Tech. 2003;60:540–51.
14. Naz S, Bashir M, Ranganathan P, Bodapati P, Santosh V, Kondaiah P. Protumorigenic actions of s100a2 involve regulation of pi3/akt signaling and functional interaction with smad3. Carcinogenesis. 2014;35:14–23.
15. Bartling B, Rehbein G, Schmitt WD, Hofmann HS, Silber RE, Simm A. S100a2-s100p expression profile and diagnosis of non-small cell lung carcinoma: impairment by advanced tumour stages and neoadjuvant chemotherapy. Eur J Cancer. 2007;43:1935–43.
16. Emberley ED, Murphy LC, Watson PH. S100 proteins and their influence on pro-survival pathways in cancer. Biochem Cell Biol. 2004;82:508–15.
17. Mishra SK, Siddique HR, Saleem M. S100a4 calcium-binding protein is key player in tumor progression and metastasis: Preclinical and clinical evidence. Cancer Metastasis Rev. 2012;31:163–72.
18. Salama I, Malone PS, Mihaimeed F, Jones JL. A review of the s100 proteins in cancer. Eur J Surg Oncol. 2008;34:357–64.
19. Wicki R, Franz C, Scholl FA, Heizmann CW, Schafer BW. Repression of the candidate tumor suppressor gene s100a2 in breast cancer is mediated by site specific hypermethylation. Cell Calcium. 1997;22:243–54.
20. Wolf S, Haase-Kohn C, Pietzsch J. S100a2 in cancerogenesis: a friend or a foe? Amino Acids. 2011;41:849–61.
21. Bulk E, Sargin B, Krug U, Hascher A, Jun Y, Knop M, et al. S100a2 induces metastasis in non-small cell lung cancer. Clin Cancer Res. 2009;15:22–9.
22. Diederichs S, Bulk E, Steffen B, Ji P, Tickenbrock L, Lang K, et al. S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer. Cancer Res. 2004;64:5564–9.
23. Ishii A, Suzuki M, Satomi K, Kobayashi H, Sakashita S, Kano J, et al. Increased cytoplasmic s100a6 expression is associated with pulmonary adenocarcinoma progression. Pathol Int. 2009;59:623–30.
24. De Petris L, Orre LM, Kanter L, Pernemalm M, Koyi H, Lewensohn R, et al. Tumor expression of s100a6 correlates with survival of patients with stage i non-small-cell lung cancer. Lung Cancer. 2009;63:410–7.
25. Melle C, Ernst G, Schimmel B, Bleul A, von Eggeling F. Colon-derived liver metastasis, colorectal carcinoma, and hepatocellular carcinoma can be discriminated by the ca(2+)-binding proteins s100a6 and s100a11. PLoS One. 2008;3:e3767.
26. Mischke D, Korge BP, Marenholz I, Volz A, Ziegler A. Genes encoding structural proteins of epidermal cornification and s100 calcium-binding proteins form a gene complex (“epidermal differentiation complex”) on human chromosome 1q21. J Investig Dermatol. 1996;106:989–92.
27. Luu HH, Zhou L, Haydon RC, Deyrup AT, Montag AG, Huo D, et al. Increased expression of s100a6 is associated with decreased metastasis and inhibition of cell migration and anchorage independent growth in human osteosarcoma. Cancer Lett. 2005;229:135–48.
28. McKiernan E, McDermott EW, Evoy D, Crown J, Duffy MJ. The role of s100 genes in breast cancer progression. Tumor Biol. 2011;32:441–50.
29. Nonaka D, Chiriboga L, Rubin BP. Differential expression of s100 protein subtypes in malignant melanoma, and benign and malignant peripheral nerve sheath tumors. J Cutan Pathol. 2008;35:1014–9.
30. Ohuchida K, Mizumoto K, Ishikawa N, Fujii K, Konomi H, Nagai E, et al. The role of s100a6 in pancreatic cancer development and its clinical implication as a diagnostic marker and therapeutic target. Clin Cancer Res. 2005;11:7785–93.
31. Slomnicki LP, Nawrot B, Legniak W. S100a6 binds p53 and affects its activity. Int J Biochem Cell Biol. 2009;41:784–90.